Stock Analiz

Sunshine Biopharma Inc. SBFM

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$2.70Market cap $2M
Open the interactive analysis →

Sunshine Biopharma Inc. (SBFM) is a healthcare company listed in the US with a market value of about $2M. In the twelve months to September 30, 2026 it had revenue of $35M and net income of -$6M, a net margin of -17.5%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (2/5); the weakest is shareholder returns (0/5).

Key numbers: 5-year revenue growth of 248% a year, a 5-year average ROIC of -54%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 890% above the current price.

About Sunshine Biopharma

Sunshine Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $1708 in 2015 to $36M in 2025, growth of about 170.9% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 51853% over three years (dilution for shareholders). It spends 2% of revenue on research and development.

Score: 1.2 / 5

Value1/5
Future growth2/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.1
P/B0.1
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-247.5%
Shareholder yield0.0%
Intrinsic value vs. price+890%

Growth and quality

Revenue growth (1 yr)4.1%
Revenue growth (5 yrs, per year)247.7%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1222.0%
ROIC (5-yr avg.)-54.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$35M$36M$35M$24M$4M$228426$71410$21121$0$0$0
Net income-$6M-$6M-$5M-$5M-$27M-$12M-$3M-$2M-$2M-$1M-$3M
Free cash flow—-$6M-$14M-$9M-$5M-$2M-$658490-$496658-$531656-$547238-$317621
EPS (diluted)$-7.42$-7.20$-36.60$-1756.80$-16695.58$-45153.95$-25897.12$-1422.92$-6735.15$-189.72$-94.86
Net margin-17.5%-16.5%-14.7%-18.7%-615.4%-5444.4%-3898.7%-7860.9%———
ROIC—-20.6%-22.7%-17.3%-95.3%-115.6%-55.9%—-140.7%-2917.1%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $1120.00, 41381% above the current price; targets range from $1120.00 to $1120.00; the consensus rating is “none”; expected EPS is $-39.00 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Sunshine Biopharma stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 890% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Sunshine Biopharma pay a dividend?

Not currently.

Is Sunshine Biopharma a good stock to buy?

We do not give buy or sell advice. Sunshine Biopharma scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.